Last reviewed · How we verify
NCT04829565
Assessment of Pain After Intra-articular Botulinum Toxin Injections in Carpometacarpal Osteoarthritis of the Thumb
Phase 4 trial testing Botulinum toxin in Rhizarthrosis in 60 participants. Participants enrolled and being followed up; not accepting new ones.
15 May 2025
Quick facts
| Lead sponsor | Centre Hospitalier Universitaire de Nice |
|---|---|
| Phase | Phase 4 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 9 September 2021 |
| Primary completion | 15 May 2025 |
| Estimated completion | 15 May 2026 |
| Sites | 1 location across France |
Drugs / interventions tested
- Botulinum toxin — full drug profile →
- Placebo
Conditions studied
- Rhizarthrosis — all drugs for Rhizarthrosis →
Sponsor
Centre Hospitalier Universitaire de Nice
Who can join
18 and older, any sex, with Rhizarthrosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Only 4 randomized controlled clinical trials have been published to date to assess the short-term effectiveness of intra-articular Botulinum Toxin injection on pain, function and quality of life in patients suffering from chronic knee pain related or not to knee osteoarthritis and also in the context of ankle osteoarthritis. The analgesic properties and the reported safety make intra-articular Botulinum toxin a strong candidate in the treatment of symptomatic manifestations of osteoarthritis disease and more particularly in certain locations such as the trapezo-metacarpal joint. Investigators hypothesize that injection of intra-articular Botulinum toxin into the trapezo-metacarpal joint will be of benefit in reducing pain and improving function in patients with rhizarthrosis. Investigators will begin a monocentric randomized controlled trial comparing intra-articular injections of Botulinum toxin and placebo.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04829565
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Botulinum toxin
Trials testing the same drug.
- NCT07303582 — Individualised Cryoneurolysis to Treat Pain in the Context of Spasticity in the Upper and Lower Extremities · Phase 4 · recruiting
- NCT06386848 — Strategy to Adapt Botulinum Toxin Doses in Dystonia · unknown
- NCT06593821 — Effect of Different Treatment Techniques on Masseter Muscle Thickness · NA · completed
- NCT06080438 — Effect of Topical Botulinum Toxin Eyedrop on Palpebral Fissure · Phase 4 · terminated
- NCT05403710 — Botulinum Toxin Therapy in Hidradenitis Suppurativa · recruiting
Other recruiting trials for Rhizarthrosis
Currently open trials in the same condition.
- NCT06781554 — Evaluation of the Performance and Safety of a Type I Collagen-Based Medical Device (MD-Small Joints Collagen Medical Dev · NA · recruiting
Other Centre Hospitalier Universitaire de Nice trials
Trials by the same sponsor.
- NCT05897996 — Percutaneous Anastomosis Creation for Hemodialysis Access · NA · withdrawn
- NCT07499869 — INNOVATIVE BENEFITS OF A 4D VIRTUAL SIMULATOR · NA · not yet recruiting
- NCT07492251 — Upadacitinib in Adult Patients With Erosive Mucosal Lichen Planus and Lichen Planopilaris: a Prospective Multicenter Ran · Phase 2 · not yet recruiting
- NCT07511608 — Development of a New Technique for Quantifying Mitochondrial DNA in Single Muscle Fibers · NA · not yet recruiting
- NCT07582406 — Codesign, Physical Activity, and Seniors · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04829565 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire de Nice
- Last refreshed: 3 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04829565.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing